All News
#ACR23 Abs #1032 identified six major themes of diverse patient experiences. Studying patient experiences is critical for understanding mechanisms of health disparity, targeting interventions and, ultimately, improving quality of care. https://t.co/Fd2m4yzlHp @rheumnow https://t.co/EhIIF9cquQ
Dr. Rachel Tate ( View Tweet)
OA and Microbiome!
Ab#1581 @RheumNow #ACR23
Microbiome transplantation of mouse models - benefit if before or soon after OA induction (meniscal destabilization)
⭐️OA is inflammatory dis of innate immune sys, not "wear-and-tear" and gut biome may be a 🔑 https://t.co/eA8unUBnpC
Eric Dein ( View Tweet)
How does Dr. Robert Spiera manage GCA?
1) Tx with steroids alone, taper by 6 months
2) Do not chase ESR/CRP
3) Pay attention to steroid complications
4) Low threshold to use IL-6i
Similar plan for PMR
Taper steroids by month 4
@RheumNow #ACR23 https://t.co/KSwyfjobFY
Robert B Chao, MD ( View Tweet)
Still uncomfortable with IL-6i in GCA or PMR especially given the pt population and potential AE?
Be on the look out for NEW biologics!
Mavrilimumab
Secukinumab
and MORE!
@RheumNow #ACR23 https://t.co/gdcDIcvffa
Robert B Chao, MD ( View Tweet)
More vitamin D during pregnancy is better, right?
Hopkins Lupus cohort, vit D levels & adverse pregnancy outcomes
Actually, there's a sweet spot
(too high just as unfavourable as too low)
Maybe popping vit D pills isn't always limitless
@jhrheumatology #ACR23 ABST1364 @RheumNow https://t.co/TVPCqP3dq9
David Liew drdavidliew ( View Tweet)
Pregnancy Updates That Will Change The Way I Practice
Dr. Rachel Tate ( @uptotate) shares two abstracts related to autoimmune patients and pregnancy risks, and her take home practice updates. #ACR23
https://t.co/X85lkKpcea https://t.co/djDujw810T
Dr. John Cush RheumNow ( View Tweet)
The great debate: Dr. Robert Spiera on why advanced therapies should not be used first-line in GCA and PMR 👇
#ACR23 @Rheumnow https://t.co/O7jtpfkoRw
sheila ( View Tweet)
Plants For Joints continuation data poster was meant to be this am #ACR23 - but withdrawn.
Makes me sad!
Intervention: plant-based diet, exercise, stress Rx for 16w
Abstract reports 1y follow-up:
sustained DAS improvement, despite BMI reductions rebounding
Enticing
@RheumNow https://t.co/4adYf5BTtt
David Liew drdavidliew ( View Tweet)
The Great Debate #ACR23 - and it’s a cracker.
Is early steroid-sparing therapy justified in GCA/PMR? I don’t know, but Rob Spiera and @philseo will battle it out to tell us.
(and ably moderated by the always eloquent @SattuiSEMD)
I’ll put some highlights here ⬇️🧵
@RheumNow https://t.co/ASpuglyENv
David Liew drdavidliew ( View Tweet)
So firstly the no case, and Rob Spiera takes up the case, dictated by the electronic coin toss.
No-one disagrees that we need steroid-sparing options, or that IL-6Ri work in PMR and GCA. But it’s the strategy questions which remain in play:
#ACR23 @RheumNow https://t.co/I2QDU7l6DE
David Liew drdavidliew ( View Tweet)
ACR#23 Abs #1023: IgG4-RD males > likely (vs females) to have multi-organ & serological activity w/ ^ immunoglobulin concentrations. Interestingly, lower lipase levels observed in males are consistent with greater degrees of pancreatic damage. https://t.co/4hUGmzTQqX @rheumnow https://t.co/kcy5dL62Pn
Dr. Rachel Tate ( View Tweet)
Great work @sharoncowley01 https://t.co/llUF6REOFR https://t.co/Ej8fQlTNH0
Barry O'Shea ( View Tweet)
⭐️Real world data on use of #avacopan presented by @zach_wallace_md
#vasculitis
Important observations to inform the practice and management of #AAV https://t.co/gtZORcnt9t
KenWarringtonMD MdWarrington ( View Tweet)
Fantastic presentation by @sharoncowley01 🚀
~1/5 patients with PMR have US evidence of Vasculitis at time of diagnosis without clinical signs of GCA
⬆️role of US in these patients https://t.co/wSs3IB8SU7 https://t.co/mAhFDVJJ8T
Caoilfhionn Connolly ( View Tweet)
#ACR23
Scleroderma renal Crisis (SRC)
May precede skin involvement also.
RISK FACTORS
• Early diffuse skin disease
- 2-3 years from SSc onset, median 8 months
• Anti-RNA polymerase III (60%)
• Use of corticosteroids
- >15 mg/d or low doses for longer time https://t.co/RSIxEXLdX7
Aditya Burje AdityaBurje ( View Tweet)
Extrahepatic manifestations of #hepatitisC #ACR23 https://t.co/sb0AQofkvt
dr hanady manasfi hanadymanasfi ( View Tweet)
#ACR23 #ReviewCourse - By Dr. Francesco Boin. Systemic Sclerosis Screening for Organ Involvement. This slide is a true "take home slide" @ACRheum #ACRambassador https://t.co/4FVYWJjHyV
Anne Troldborg ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on Update on Relapsing Polychondritis - Dr. Marcela Ferrada
1. Be aware of common/uncommon manifestations (see slide). Affects more than just the ear!!!
2. Collagen II antibodies: not really sensitive or specific for diagnosis. Biopsy… https://t.co/f5xGtcMzk3 https://t.co/xVigSabXDb
Paul Sufka, MD psufka ( View Tweet)
What a talk. @DrPujaMehta1 on the big stage, with a truly inspirational talk in the #ACR23 Daltroy Lecture.
If you have any thoughts at all on DEI, or just are curious, you need to watch this.
I need to listen to it again, but two initial key points for me:
@RheumNow https://t.co/G4lngvpdS7
David Liew drdavidliew ( View Tweet)
Colchicine - what a fascinating medicine.
From a rheum point of view, interesting to see it play out for secondary prevention coronary artery disease, lot of patients. Great we can share our collective clinical confidence with it with cardiology
#ACR23 @US_FDA session @RheumNow https://t.co/Q7zLtyby8l
David Liew drdavidliew ( View Tweet)
